secwatch.observer — SEC 8-K summary
======================================

Issuer:     ESTABLISHMENT LABS HOLDINGS INC. (ESTA)
CIK:        0001688757
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001688757-24-000088
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Establishment Labs Q3 revenue $40.2M, cuts 2024 guidance to $165-168M, raises $50M in direct offering
--------------------------------------------------------------------------------

- Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.
- 2024 revenue guidance reduced to $165-168M from prior $174-184M due to FDA delay and Brazil weakness.
- Cash $39.7M at Sep 30; pro forma $114M after $25M Oaktree draw and $50M registered direct offering (5% discount).
- FDA approved Motiva Implants Sep 26; U.S. launch added 250+ accounts in first three weeks; expects >$35M U.S. revenue in 2025.
- Oaktree facility amended: $25M Tranche D available through Dec 31, 2025 subject to revenue milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1688757/000168875724000088/0001688757-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1688757/000168875724000088/esta-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001688757-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer